

Oncology Today with Dr Neil Love: Optimizing Biomarker Assessment and Related Treatment Decision-Making for Patients with HR-Positive Metastatic Breast Cancer

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. What is the optimal method for ESR1 mutation testing for patients with ER-positive breast cancer?**
 - Immunohistochemistry
 - Fluorescence in situ hybridization
 - Next-generation sequencing (NGS) tissue biopsy
 - NGS liquid biopsy
- 2. The Phase III CAPitello-291 study evaluating fulvestrant with capivasertib versus fulvestrant alone for patients with HR-positive metastatic breast cancer who experienced disease progression on an aromatase inhibitor (AI) with or without CDK inhibitor demonstrated which of the following concordance frequencies between liquid and solid biopsy for detecting PI3K pathway alterations?**
 - 39%
 - 53%
 - 77%
 - 92%
- 3. Per the INAVO120 study of patients with HR-positive metastatic breast cancer whose disease progressed on adjuvant endocrine therapy, which of the following is now recommended?**
 - Baseline sequencing for PIK3CA mutations
 - Baseline sequencing for ESR1 mutations
 - Baseline sequencing for both PIK3CA mutations and ESR1 mutations
 - Baseline sequencing for neither PIK3CA mutations nor ESR1 mutations
- 4. Which of the following statements best describes the SERENA-6 study of HR-positive, HER2-negative advanced breast cancer?**
 - Phase II trial of camizestrant with a CDK4/6 inhibitor after disease progression on CDK4/6 inhibitor therapy
 - Phase II/III trial of camizestrant versus an AI with a CDK4/6 inhibitor for treatment-naïve disease
 - Phase III trial of therapeutic switching from an AI to camizestrant with the same CDK4/6 inhibitor for patients with detectable ESR1 mutations in circulating tumor DNA and no evidence of disease progression
- 5. In the Phase III evERA study evaluating giredestrant and everolimus compared to standard endocrine therapy and everolimus for patients with HR-positive, HER2-negative metastatic breast cancer previously treated with a CDK4/6 inhibitor, what percent of study participants had ESR1 mutations?**
 - 28%
 - 56%
 - 71%